Toronto, April 13, 2018 (GLOBE NEWSWIRE) -- Dr. Rafi Hofstein, President and CEO of MaRS Innovation (MI) announced today that as part of Toronto Health Innovation Week, MI will lead…
TORONTO, ON--(Marketwired - April 18, 2017) - MaRS Innovation (MI) and its South Korean partner, Korea Health Industry Development Institute (KHIDI), continue to build on the five-year global partnership agreement signed…
TORONTO (February 13, 2017): QD Solar, a Canadian technology company created by MaRS Innovation and the University of Toronto, announced today the closing of a C$2.5M Series A funding led…
Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for…
BresoTec, formerly known as ApneaDx, also among top five finalists
TORONTO, August 11, 2015 – Legworks‘ next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.
Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS Discovery District from August 8 to 10, 2015.
Legworks was one of five companies to make it to the final round of the competition.
Other finalists were Eightfold Technologies, MyndTec, BresoTec Inc., and Komodo OpenLabs. BresoTec Inc., formerly known as ApneaDx Inc., is a MaRS Innovation start-up company spun-off in partnership with the University Health Network’s Toronto Rehabilitation Institute and is developing a medical device to allow patients to determine whether they have sleep apnea without having to visit a sleep clinic.
The Medical Sciences Proof-of-Principle (MSc PoP) program, administered by Ontario Centres of Excellence on behalf of Ontario’s Ministry of Research & Innovation, is a province-wide initiative for which MaRS Innovation accepts applications from our 15 member institutions.
MaRS Innovation is currently recruiting applications for the
July 30, 2015 August 27, 2015 (2 pm) deadline; for submissions to be considered via MI, paperwork must be in byAugust 24, 2015 (4 pm).
We’ve also learned there will be a second call for MScPoP applications in January 2016 after the current round has closed. The third and final call for applications is scheduled for September 2016. All programs will be run using the same criteria (see below).
CQDM and MaRS Innovation investing in new Encycle project to determine rules for making peptide drugs orally bioavailable
PHILADELPHIA (June 16, 2015) — FiercePharma has predicted that the pharmaceutical industry stands to lose $44 billion in drugs going off patent in 2015. The industry is searching for new therapeutics to replenish their pipelines while tackling existing and new drug receptor targets within the cell, improve patient care and lower administrative costs. In this context, drugs that can be orally swallowed, known as orally-bioavailable drugs, are in great demand.
Encycle Therapeutics Inc., a biotechnology company founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is a Canadian start-up emerging as a market leader in finding orally-bioavailable molecules. Today, the company announced $840,000 in funding from CQDM and MaRS Innovation to generate a better understanding of the chemical properties required to make small peptide-like molecules, which Encycle calls nacellins, orally bioavailable.
This funding, generated through MaRS Innovation’s strategic partnerships programs with Pfizer Inc. and GSK, and CQDM’s global membership program with Pfizer Inc. and Merck, brings Encycle’s total funding to approximately $4 million, including an earlier investment in 2011 from Ontario Centres of Excellence.
Dr. Diane Gosselin, president and CEO of CQDM, together with Dr. Raphael (Rafi) Hofstein, president and CEO of MaRS Innovation, made the announcement this morning at the 2015 BIO International Convention in the presence of Dr. Reza Moridi, Ontario Minister of Research and Innovation and Minister of Training, Colleges and Universities, and Dr. Gaétan Barrette, Quebec Minister of Health and Social Services.
“Encycle’s proprietary cyclized peptides are very different from other types of therapeutics and should enable us to target many of the proteins that are currently regarded as undruggable,” says Dr. Jeffrey Coull, Encycle’s president and CEO. “Our research suggests that, due to their unique properties, it’s easier for our peptides to cross cell membranes than it is for other types, allowing them to be taken orally and access proteins on the inside of a cell. Working on this project together with Pfizer and Merck through CQDM, as well as Pfizer and GSK through MaRS Innovation, we now wish to develop a more precise understanding of the relationship between their structure and composition, and the ability to be delivered orally.”
Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies
TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer’s disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million contribution to the Neuroscience Catalyst consortium, bringing the total raised for the open innovation fund to $3.7 million. Reza Moridi, Minister of Research and Innovation and Minister of Training Colleges and Universities, announced the contribution at the 2015 BIO International conference in Philadelphia during the opening of the Ontario pavilion.
This release was covered by Pharma TV and in TechVibes, BioSpace and Biotechnology Focus, and was referenced on the Canadian Science Policy Centre‘s and the Alzheimer Society of Toronto’s respective websites.
“We are pleased to support this collaborative innovation model which will accelerate the development of better treatment options for people with neurological disorders,” said Minister Moridi. “Partnerships between universities, academic hospitals, research institutes, industries and government are key to positioning Ontario as a global leader in Life Sciences.”
Founded by the University of Toronto (U of T) in partnership with Janssen Inc. and facilitated by Johnson & Johnson Innovation, the Neuroscience Catalyst consortium is using the Toronto research community’s well-established strengths in neuroscience to identify promising early-stage molecules and technologies through an open innovation model. The consortium aims to combine expertise to enable and accelerate the translation of basic sciences through to start-up companies and investor partnerships.
“We all want the next generation of solutions that are so desperately needed by patients and their families,” said Professor Ruth Ross, director of the Centre for Collaborative Drug Research at U of T. “In Canada, mood disorders such as depressive disorder and bipolar disorder affect about 10 per cent of the population. Alzheimer’s disease affects more than 745,000 Canadians. The need is urgent and this unique open collaborative partnership will allow us to rapidly develop new treatments.”
Other partners joining the project include MaRS Innovation, which introduced the partners to the Ministry of Research & Innovation and led the early conversation; Evotec, a global, high-quality provider in the drug discovery field; and Ontario Centres of Excellence (OCE), which is administering the funding.
Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP).
The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications Partnership Program (GAPP), on October 15 in Wallenstein, Ontario.
The project titled “Development of Low Cost Testing Chip and Device for Hepatitis C Testing” was approved with funding up to a maximum of $5,999,865 over three years. The Ontario Ministry of Research and Innovation is supporting the project with a grant matching the Genome Canada contribution.
“This is a tremendous opportunity for us to leverage the viral assay development and electrochemical detection expertise in the labs of Dr. Shana Kelley and Dr. Edward Sargent at the University of Toronto to significantly advance our own research programs on several fronts,” said Dr. Graham D. Jack, Xagenic’s senior director of Research and Development. “Under this joint program, we anticipate development of a new lower-cost substrate chip, which will significantly bring down the total cost of our in-cartridge AuRA™ detection technology.
Timothy I. Still appointed Xagenic’s president and CEO
On October 16, 2014, Xagenic also announced that Timothy I. Still has been appointed president and CEO, and will serve as a member of Xagenic Inc.’s board of directors.
This announcement was covered in PE Hub.
TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC).
This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity.
Today’s financing builds on prior support from the Ontario Centres of Excellence (OCE), the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP), Ontario Ministry of Research and Innovation’s Business Accelerator Program (MRI-BAP) and other Canadian life science development organizations.
“This financing round enables us to rapidly advance our lead ADC into clinical trials,” said Ilia Tikhomirov, President and CEO. “We would like to thank the NRC and all of our partners for their support as AvidBiologics transitions from a discovery-stage to a development-stage company.”
“The high quality pre-clinical package and exceptional leadership team, including pioneers in the development of ADCs, position the company for a successful transition towards clinical development,” said Dr. Raphael Hofstein, president and CEO of MI. “The cooperation among funding organizations, such as those involved in this financing, represents the strengthening foundation on which commercialization within Toronto’s start-up community can be successfully realized. We are glad to be part of this financing syndicate that supports one of Canada’s leading life sciences companies.”